141 related articles for article (PubMed ID: 31937861)
21. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L
Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504
[TBL] [Abstract][Full Text] [Related]
22. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
[TBL] [Abstract][Full Text] [Related]
23. Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Angst D; Gessier F; Janser P; Vulpetti A; Wälchli R; Beerli C; Littlewood-Evans A; Dawson J; Nuesslein-Hildesheim B; Wieczorek G; Gutmann S; Scheufler C; Hinniger A; Zimmerlin A; Funhoff EG; Pulz R; Cenni B
J Med Chem; 2020 May; 63(10):5102-5118. PubMed ID: 32083858
[TBL] [Abstract][Full Text] [Related]
24. Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.
Yao X; Sun X; Jin S; Yang L; Xu H; Rao Y
J Med Chem; 2019 Jul; 62(14):6561-6574. PubMed ID: 31260299
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
Zheng N; Hao Q; Lin K; Pan J; Li Y; Zhou W
Bioorg Med Chem Lett; 2019 Jan; 29(2):225-229. PubMed ID: 30522954
[TBL] [Abstract][Full Text] [Related]
26. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
27. BTK: a two-faced effector in cancer and tumour suppression.
Rada M; Barlev N; Macip S
Cell Death Dis; 2018 Oct; 9(11):1064. PubMed ID: 30337526
[TBL] [Abstract][Full Text] [Related]
28. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
Liu H; Zhang T; Chen R; McConkey DJ; Ward JF; Curley SA
J Surg Res; 2012 Jul; 176(1):147-53. PubMed ID: 22099584
[TBL] [Abstract][Full Text] [Related]
29. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B
Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225
[TBL] [Abstract][Full Text] [Related]
30. Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors.
Tintori C; La Sala G; Vignaroli G; Botta L; Fallacara AL; Falchi F; Radi M; Zamperini C; Dreassi E; Dello Iacono L; Orioli D; Biamonti G; Garbelli M; Lossani A; Gasparrini F; Tuccinardi T; Laurenzana I; Angelucci A; Maga G; Schenone S; Brullo C; Musumeci F; Desogus A; Crespan E; Botta M
J Med Chem; 2015 Jun; 58(11):4590-609. PubMed ID: 25923950
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.
Zhai Z; Li R; Bai X; Ning X; Lin Z; Zhao X; Jin Y; Yin Y
Bioorg Med Chem; 2019 Sep; 27(18):4124-4142. PubMed ID: 31395509
[TBL] [Abstract][Full Text] [Related]
32. Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.
Ma B; Bohnert T; Otipoby KL; Tien E; Arefayene M; Bai J; Bajrami B; Bame E; Chan TR; Humora M; MacPhee JM; Marcotte D; Mehta D; Metrick CM; Moniz G; Polack E; Poreci U; Prefontaine A; Sheikh S; Schroeder P; Smirnakis K; Zhang L; Zheng F; Hopkins BT
J Med Chem; 2020 Nov; 63(21):12526-12541. PubMed ID: 32696648
[TBL] [Abstract][Full Text] [Related]
33. Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
Wang C; Li S; Meng Q; Sun X; Li H; Shu X; Sun H; Liu K; Liu Z; Ma X
Bioorg Med Chem; 2018 Aug; 26(14):4179-4186. PubMed ID: 30006143
[TBL] [Abstract][Full Text] [Related]
34. Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series.
Liu Q; Batt DG; Chaudhry C; Lippy JS; Pattoli MA; Surti N; Xu S; Carter PH; Burke JR; Tino JA
Bioorg Med Chem Lett; 2018 Oct; 28(18):3080-3084. PubMed ID: 30097367
[TBL] [Abstract][Full Text] [Related]
35. Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
Liu L; Li X; Cheng Y; Wang L; Yang H; Li J; He S; Shuangjie Wu ; Yin Q; Xiang H
Eur J Med Chem; 2019 Feb; 164():304-316. PubMed ID: 30605829
[TBL] [Abstract][Full Text] [Related]
36. Calix[6]arene bypasses human pancreatic cancer aggressiveness: downregulation of receptor tyrosine kinases and induction of cell death by reticulum stress and autophagy.
Pelizzaro-Rocha KJ; de Jesus MB; Ruela-de-Sousa RR; Nakamura CV; Reis FS; de Fátima A; Ferreira-Halder CV
Biochim Biophys Acta; 2013 Dec; 1833(12):2856-2865. PubMed ID: 23872419
[TBL] [Abstract][Full Text] [Related]
37. A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation.
Lopez-Tapia F; Lou Y; Brotherton-Pleiss C; Kuglstatter A; So SS; Kondru R
Bioorg Med Chem Lett; 2019 May; 29(9):1074-1078. PubMed ID: 30857747
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
Gilardini Montani MS; Granato M; Santoni C; Del Porto P; Merendino N; D'Orazi G; Faggioni A; Cirone M
Cell Oncol (Dordr); 2017 Apr; 40(2):167-180. PubMed ID: 28160167
[TBL] [Abstract][Full Text] [Related]
39. Fyn requires HnRNPA2B1 and Sam68 to synergistically regulate apoptosis in pancreatic cancer.
Chen ZY; Cai L; Zhu J; Chen M; Chen J; Li ZH; Liu XD; Wang SG; Bie P; Jiang P; Dong JH; Li XW
Carcinogenesis; 2011 Oct; 32(10):1419-26. PubMed ID: 21642356
[TBL] [Abstract][Full Text] [Related]
40. Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells.
Wang F; Wang Q; Zhou ZW; Yu SN; Pan ST; He ZX; Zhang X; Wang D; Yang YX; Yang T; Sun T; Li M; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():537-60. PubMed ID: 25632222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
